biology-products/pds-1000-he-system-from-bio-rad-1554-1/;+health+history;+medical+history.html

Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2 Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3 Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4 Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2 Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3 Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2 Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2

[0] Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans [0] Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development [0] Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology [0] Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference

Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Dynatronics Receives 180-Day NASDAQ Extension 2 Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2 YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1 YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2 YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3 OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1 OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2 Fitness Might Limit Strokes Impact 51687 1 Fitness Might Limit Strokes Impact 51687 2

[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer [0] Dynatronics Receives 180-Day NASDAQ Extension [0] Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline